Cited by 66Alzheimer's disease research and treatmentsGenetic Associations and EpidemiologyDementia and Cognitive Impairment Research

Novel polymorphism in the A4 region of the amyloid precursor protein gene in a patient without Alzheimer's disease

Peacock, Michael L., Warren, James T., Roses, Allen D., Fink, John K.·1993·Neurology

Abstract

We found a novel polymorphism in the amyloid precursor protein (APP) gene in a patient with ischemic cerebrovascular disease who had no evidence of Alzheimer's disease (AD). This polymorphism deletes a Fok I restriction enzyme site and causes the substitution of threonine for alanine at codon 673. This is adjacent to the site at which APP is thought to undergo cleavage in AD. Analysis of this polymorphism may provide insight into the basis of APP processing.

Integrity signals

Registry

Crossref · 10.1212/wnl.43.6.1254

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Despite sparse parenchymal amyloid deposition, the Icelandic APP mutation leads to mild CAA and vascular pathology including microinfarcts and ischemic stroke.

    “Interestingly, despite sparse parenchymal amyloid deposition, the Icelandic mutation leads to mild CAA and vascular pathology including microinfarcts (311) and ischemic stroke (468), suggesting vascular vulnerability.”

    From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [468]

Cited by

Sorted by citations

Authors
Peacock, M. L., Warren, J. T., Roses, A. D., & Fink, J. K.
Affiliations
Duke University (US)
Venue
Neurology
Published
1993-06
Volume
43
Issue
6
Pages
1254-1254
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2076562792
Cited by
66
References
0
Citations by year
2026: 1 · 2025: 4 · 2024: 3 · 2023: 2 · 2022: 3 · 2021: 1 · 2020: 3 · 2019: 4 · 2018: 3 · 2017: 3 · 2016: 4 · 2015: 4 · 2014: 5 · 2013: 1 · 2012: 2
FWCI
1.08
Type
journal article
Language
en
Open access
closed
Locations
  • Neurology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5r01ag010691-02)
  • National Institute on Aging (R01-AG10691, AG05 128, P50AG005128, NIA AG 07922)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
amyloid precursor protein, Alzheimer's disease, genetic variation, positive selection, soft sweeps, hard sweeps, deleterious mutations, sexual selection, cancer risk, central nervous system development
MeSH terms
Alzheimer Disease, Cerebrovascular Disorders, Humans, Polymorphism, Genetic, Reference Values, Amyloid beta-Protein Precursor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review